The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Millennium
Stock and Other Ownership Interests - Takeda
Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1.
 
María-Victoria Mateos
Honoraria - Celgene; Janssen; Millennium
 
Tamas Masszi
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen-Cilag; Novartis; Takeda
 
Norbert Grzasko
No Relationships to Disclose
 
Markus Hansson
No Relationships to Disclose
 
Irwindeep Sandhu
Honoraria - Amgen; Celgene; Janssen; Lundbeck; Novartis
 
Ludek Pour
No Relationships to Disclose
 
Luisa Viterbo
No Relationships to Disclose
 
Sharon R. Jackson
No Relationships to Disclose
 
Anne-Marie Stoppa
Honoraria - Takeda
 
Peter Gimsing
Honoraria - Amgen
 
Mehdi Hamadani
Consulting or Advisory Role - Cellerant; MedImmune
Speakers' Bureau - Celgene
Research Funding - Takeda (Inst)
 
Gabriela Borsaru
No Relationships to Disclose
 
Deborah Berg
No Relationships to Disclose
 
Jianchang Lin
Employment - Millennium
 
Helgi Van De Velde
Employment - Millennium
Stock and Other Ownership Interests - Takeda
 
Paul G. Richardson
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Genmab; Johnson & Johnson; Millennium; Novartis; Oncopeptides
Research Funding - Celgene; Millennium
 
Philippe Moreau
Consulting or Advisory Role - Amgen; Celgene; Janssen; Novartis; Takeda